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This article presents two cases of opportunistic mycoses (OMs) of the central nervous system (CNS) caused 
by Cryptococcus neoformans and Aspergillus nidulans, respectively. The patients were hospitalised in 
local hospitals between 2009 and 2011 because of unspeciﬁ c symptoms (fever, headache, and/or weight 
lost). Duration of symptoms varied from 4 days to over 2 weeks. The patients were treated with antibiotics 
and symptomatically. OM was not suspected in any of them. The patients became critically ill with symptoms 
of CNS involvement and were transferred to the Intensive Care Unit (ICU) of the University Hospital for 
Infectious diseases (UHID) in Zagreb. None of the patients belonged to the high-risk population for 
developing OMs. They were not HIV-infected, had no transplantation of bone marrow or solid organ, and 
were not on severe immunosuppressive chemotherapy. Fungi were isolated from cerebrospinal ﬂ uid (CSF) 
samples and, in one patient, from aspirate of cerebral abscess. Isolation and mycological identiﬁ cation of 
all fungal isolates and in vitro antifungal susceptibility testing of these isolates were done at the Reference 
Centre for Mycological Diagnostics of Systemic and Disseminated Infections (RCMDSDI) in Zagreb. The 
patient with cryptococcal meningitis was treated with amphotericin B and ﬂ uconazole and the patient with 
cerebral aspergilloma with voriconazole.
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* The subject of this article has partly been presented at the International 
Symposium “Power of Fungi and Mycotoxins in Health and Disease” held in 
Primošten, Croatia, from 19 to 22 October 2011.
The incidence of opportunistic mycoses (OMs) is 
increasing at an alarming rate, presenting an enormous 
challenge to healthcare professionals (1). This increase 
is directly related to the ever-growing population of 
immunocompromised patients, including individuals 
undergoing blood and bone marrow transplantation, 
solid organ transplantation, major surgery, those with 
HIV/AIDS, neoplastic diseases, and immunosuppressive 
therapy (1). This group of high-risk hosts has recently 
been extended to apparently immunocompetent 
intensive care unit (ICU) patients and persons with 
anatomic abnormalities (1).
The most common causes of OMs include Candida 
albicans and Aspergillus fumigatus (1). In addition to 
these agents, increasingly important is the growing 
list of opportunistic yeasts and moulds that includes 
non-albicans Candida species, non-fumigatus 
Aspergillus species, Cryptococcus neoformans, yeast-
like fungi such as Trichosporon spp., Malassezia spp., 
Rhodotorula spp., the zygomycetes, hyaline moulds 
such as Fusarium spp., Acremonium spp., Scedosporium 
spp., and a wide variety of dematiaceous fungi such 
as Cladophialophora spp. and Aureobasidium spp. 
(1-6).
Infections with these fungi may have various 
clinical presentations ranging from fungemia and 
disseminated infections to more localised infections 
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involving the lung, skin, and paranasal sinuses (7). 
Given the complexity of the patients at risk and the 
diverse array of fungal pathogens, OMs pose a 
considerable diagnostic and therapeutic challenge. 
Diagnosis depends on a heightened clinical suspicion 
and obtaining appropriate material for culture. 
Isolation and identiﬁ cation of the infecting organisms 
as well as in vitro antifungal susceptibility testing of 
isolates are very important in properly managing 
infections due to less common opportunistic fungi 
(1-7).
Here we report two cases of OMs of the central 
nervous system (CNS) caused by Cryptococcus 
neoformans and Aspergillus nidulans, respectively. 
The aim was to show how efficient cooperation 
between clinicians and medical mycologists can help 
the patient and to raise clinicians’ awareness of fungal 




A 27-year-old pregnant woman, 2 weeks before 
admission to ICU of the University Hospital for 
Infectious diseases (UHID) in Zagreb, presented at 
the emergency room of a local hospital with fever, 
headache, and elevated blood pressure. Since 
preeclampsia was presumed, she delivered a vital male 
premature infant by caesarean section. The symptoms 
continued for about 2 weeks and were not resolved by 
antibiotics. A few days before admission to the ICU, 
the patient’s temperature rose as high as 40.8 °C. She 
developed left-sided supranuclear facial palsy, right-
sided oculomotorius paresis and deviation of the 
tongue to the left. She had a history of episodic 
seizures, arterial hypertension, and cerebral atrophy. 
Because of oligophrenia, she had been prescribed 
atenol and carbamazepine, but these were taken 
irregularly.
On admission to the ICU, blood and cerebrospinal 
ﬂ uid (CSF) samples were taken for laboratory analysis. 
The patient’s CSF cell count was 450 mm-3 with a 
predominance of polymorphonuclear neutrophils 
(57 %). Glucose and chloride levels were low 
(0.6 mmol L-1 and 105 mmol L-1, respectively), and 
the total protein level was 1.5 g L-1. She tested negative 
for HIV-1 and HIV-2. CD4+ T-cell count was below 
300 mm-3 on two occasions (250 mm-3 and 257 mm-3, 
respectively). Despite intensive evaluation, no 
alternative explanation could be found for CD4+ 
lymphocytopenia.
Intravenous amphotericin B therapy (0.75 mg 
kg-1) was started after receiving a preliminary report 
from the Reference Centre for Mycological Diagnostics 
of Systemic and Disseminated Infections (RCMDSDI) 
indicating cryptococcosis due to the presence of 
several encapsulated budding blastoconidia in India 
ink preparation of the patient’s CSF and moderate 
elevated capsular antigen titres in CFS and serum 
samples detected by the latex agglutination (LA) test 
(Pastorex Crypto Plus, Bio-Rad). Cryptococcal 
meningitis was conﬁ rmed by cryptococcal isolation 
from patient’s CSF sample on Sabouraud’s glucose 
agar (SGA) and Brain-Heart Infusion agar (BD 
Diagnostics). Cryptococcaemia was not documented. 
CSF, blood, urine, and respiratory tract cultures did 
not show bacteria, acid fast bacilli or other fungi. C. 
neoformans isolate was identiﬁ ed using the ID32C 
method (bioMérieux) and morphology on cornmeal 
agar (BD Diagnostics). In vitro susceptibility proﬁ les 
of the C. neoformans isolate to flucytosine, 
amphotericin B, fluconazole, itraconazole, and 
voriconazole were determined with minimum 
inhibitory concentrations (MICs) using the ATB 
FUNGUS 3 (bioMerieux) microdilution method. C. 
neoformans isolate was susceptible to all tested 
antifungal agents. A follow-up lumbar puncture was 
performed ﬁ ve days after antifungal therapy started. 
The India ink and LA test were still positive for C. 
neoformans, but cryptococcal culture was negative. 
The patient’s condition improved clinically and the 
initial symptoms gradually resolved. After three 
weeks, amphotericin B was replaced by oral 
ﬂ uconazole (400 mg per day) for four weeks. During 
this period, repeated CFS and serum cryptococcal 
antigen analyses showed a persistent drop in titres. 
Microscopic CSF analysis was normal on day 16 of 
antifungal therapy. Home treatment was continued 
with oral ﬂ uconazol (200 mg per day) for a total of 
five months. Follow up CD4+ T-cell count was 
276 mm-3. The patient was otherwise well and the 
results of mycological analyses of control CSF and 
serum samples were negative.
C. neoformans is an encapsulated basidiomycetous 
yeast common in soil, especially is the one containing 
pigeon droppings (8-10). Despite the high prevalence 
of this fungus in the environment, human cryptococcosis 
is rare, except in patients with disorders of cell-
Mlinarić Missoni E, Baršić B. RARE CNS MYCOSES
Arh Hig Rada Toksikol 2012;63:505-511
507
mediated immunity such as HIV infection or 
lymphoreticular malignancies, or in patients with 
immunosuppression after steroid therapy or organ 
transplantation (11, 12).
In Croatia, nearly 900 HIV-infected persons had 
been registered from 1985, when HIV was first 
diagnosed, to December 2010 (13). The widespread 
use of highly active antiretroviral therapy (HAART) 
has lowered the incidence of cryptococcosis in HIV-
infected persons in medically developed countries and 
in Croatia (11, 13). Between 2005 and 2010, 
RCMDSDI veriﬁ ed cryptococcosis in ﬁ ve (33.3 %) 
HIV-infected patients and ten (66.7 %) non-HIV-
infected patients (13). The latter were patients with 
haematological malignancies (n=9) and one with 
idiopathic CD4+ lymphocytopenia, presented in this 
report. There was no evidence of in vitro resistance of 
clinical C. neoformans isolates to amphotericin B or 
ﬂ uconazole during this period.
C. neoformans enters the host primarily through 
the respiratory tract and causes the primary infection 
of the lung. Subsequent bloodstream dissemination 
from the lungs, usually to the CNS, produces, almost 
uniformly, fatal cryptococcal meningoencephalitis in 
susceptible individuals, if it is not diagnosed and 
treated properly (11, 12). The mycological diagnosis 
of cryptococcal meningoencephalitis is based on 
positive CSF and/or serum cryptococcal antigen 
ﬁ ndings, presence of encapsulated blastoconidia in 
India ink preparation of CSF, and/or on isolation of 
C. neoformans from CSF (14). Perfect et al. (11) have 
issued speciﬁ c recommendations for the management 
of cryptococcal meningoencephalitis in non-HIV-
infected, nontransplant hosts. The key management 
steps are induction therapy with fungicides such as 
polyene followed by consolidation and maintenance 
therapy with fluconazole (11). Thanks to such 
antifungal regimen C. neoformans was eradicated and 
our patient survived the infection without chronic 
neurological complications.
Case 2
The second 41-year-old male patient was admitted 
to the ICU of UHID due to four days of fever, headache 
and confusion. Relevant data from his medical history 
include peptic ulcer, pulmonary tuberculosis treated 
16 years earlier, tongue haemangioma operated eight 
years earlier, and a stroke as a complication of 
temporal lobe abscess 6 years earlier. After antibiotic 
treatment and surgery he recovered fully. One year 
earlier he had been diagnosed with sideropenic 
anaemia. His family history reveals that his mother 
also suffered from occasional gastrointestinal bleeding 
and sideropenia.
On admission, erythrocyte sedimentation rate was 
30 mm per hour, haemoglobin level was 103 g L-1, 
and lactate was 2.68 mmol L-1. HIV-1 and HIV-2 
infections were excluded. Laboratory data of the 
patient’s CFS sample included a total cell count of 
725 mm-3 with 70 % neutrophils, 14 % monocytes, 
6 % reactive lymphocytes, 2 % macrophages, and 1 % 
plasma cells. Total protein level was 1.5 g L-1. CSF-
blood glucose ratio was 0.54.
Brain magnetic resonance imaging (MRI) showed 
a lesion involving the right temporal and parietal lobe, 
suggestive of brain abscess (Figure 1). This intracranial 
mass was aspirated by stereotactically and sent for 
microbiological diagnosis of conventional bacteria, 
fungi, and acid fast bacilli. Routine microscopic 
examination of Giemsa-Romanowsky (GR) stained 
preparations showed the presence of fungal fragments 
with morphology consistent with hyalohyphomycetes 
other than zygomycetes (Figure 2).
Following this preliminary report from RCMDSDI, 
intravenous voriconazole [(400+0+200) mg per day] 
was initiated. Three days later, there was a signiﬁ cant 
growth of mould on SGA plates at 25 °C and 37 °C 
(Figure 3). Whitish colonies became powdery to 
granular, dark green in colour with brownish red on 
the reverse. Culture for conventional bacteria and acid 
fast bacilli remained sterile. Identiﬁ cation of Aspergillus 
nidulans was based on a characteristic microscopic 
appearance of reproductive structure (Figure 3). The 
in vitro activities of four systematically active 
antifungal agents against A. nidulans isolate were 
 a) b)
Figure 1  MRI of the brain a) post-contrast T1WI (weighted 
imaging) revealed expansive lesion in the right 
temporal and parietal lobe near the right lateral 
ventricle, with intensive ring enhancement. A mild 
perilesional oedema is also visible; b) axial T2WI of 
the same lesion. These images are consistent with 
the morphology of brain abscess.
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determined by the Etest method (AB bioMérieux). 
The activities of the new extended-spectrum triazoles 
(voriconazole and posaconazole) were considerably 
better (MICs were 0.016 μg mL-1 and 0.032 μg mL-1, 
respectively) than of amphotericin B (MIC=4 μg 
mL-1) and caspofungin (MIC=32 μg mL-1). Intravenous 
therapy with voriconazole continued for another 29 
days (30 days in total). The patient made a full clinical 
and radiological recovery. He continued to take 
voriconazole orally (2x200 mg per day for the next 3 
months.
A. nidulans, anamorph of Emericella nidulans 
(Eidam) Vuill. is an airborne hyaline mould found 
everywhere on various types of substrate, especially 
soil, and in hospital water systems (15, 16). This 
Aspergillus species has been reported as the cause 
of diverse infections in humans, either alone or in 
combination with other opportunistic fungi, 
including pulmonary or cerebral infections, 
sinusitis, endophtalmitis, osteomyelitis, eumycotic 
mycetoma, nail infections, and disseminated 
aspergillosis (15, 17-19). These infections have 
been reported almost exclusively in children with 
chronic granulomatous disease (CGD) (20). In these 
patients A. nidulans is more virulent than other 
Aspergillus species, judging by its propensity to spread 
from the lungs to adjacent structures  and the death 
rate it has in this population (17-20).
Our patient was an adult without CGD. He had no 
detectable paranasal sinus, lung, or any other organ 
involvement at the time of the clinical presentation of 
brain abscess. The patient was remarkably well 
before presenting with neurological symptoms. In 
contrast, cerebral aspergillosis arising from 
immunosuppression or malignancy is invariably 
associated with disseminated fungal disease (17-
21). Chakrabarti et al. (21) have already reported 
about cerebral aspergilloma caused by A. nidulans in 
two adult patients. They were operated on and received 
systemic therapy with amphotericin B, but the 
infection proved fatal in both.
In order to establish the underlying cause of 
cerebral aspergilloma in our patient, we thoroughly 
reviewed his medical history data and the test results. 
It turned out to be Osler–Weber-Rendu (OWR) 
syndrome. This autosomal dominant disorder, also 
known as hereditary haemorrhagic telangiectasia, is 
typically identified by multiorgan arteriovenous 
malformations (AVMs), associated haemorrhage, and 
a positive family history of the disorder (22). Cerebral 
abscess is the most common neurological manifestation 
of the OWR syndrome due to ﬁ ltering function failure 
of the pulmonary vasculature because of pulmonary 
AVMs (22).
Conventional techniques including direct 
microscopy, histopathology and culture of appropriate 
specimens remain the reference standard for 
mycological diagnosis of disseminated aspergillosis 
(15, 23). The increasing diversity of opportunistic 
hyaline moulds and their differences in susceptibilities 
 a) b) 
Figure 3  Macromorphology and micromorphology of 
Aspergillus nidulans isolated from  brain abscess 
aspirate: a) a ﬁ ve-day-old colony culture grown on 
SGA at 37 °C; b) conidial heads are short, columnar 
and biseriate in Lactophenol cotton blue mount from 
the colony. Conidiophores are short, brownish and 
smooth-walled. Conidia are globose and rough-
walled (400x magniﬁ cation).
Figure 2  The hyphae are narrow, septate, branched, of uniform 
width, variably stained by GR and stand out in sharp 
contrast to the purulent exudate. Their resemblance 
to various hyalohyphomycetes such as those of the 
Aspergillus species, Fusarium species, Acremonium 
species, Scedosporium species make the microscopic 
differentiation of these fungi difﬁ cult. The mass of 
closely septate, aberrant forms is characteristic of 
chronic lesions (1000x magniﬁ cation)
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to antifungal agents make identification of the 
infecting isolate at the species level and determination 
of its in vitro antifungal susceptibility profiles 
mandatory (15, 23). Novel systems for detection of 
circulating fungal cell wall markers and/or DNA in 
blood and other body ﬂ uids or in affecting tissues may 
improve the laboratory diagnosis of disseminated 
aspergillosis (15, 23). Our results of in vitro resistance 
to amphotericin B and susceptibility to voriconazole 
were comparable with the published data on in vitro 
activities of these antifungal agents for 13 worldwide 
clinical A. nidulans isolates from different body sites 
including brain/CSF (24). Poor response and high 
failure rates have been reported in patients with A. 
nidulans cerebral infection who were treated with 
amphotericin B (21). Surgery remains the mainstay 
of therapy in the management of cerebral aspergillosis 
followed by voriconazole (20, 21). In our patient, 
treatment with voriconazole and extensive stereotactic 
aspiration followed by prolonged treatment with the 
same antifungal agent resulted in an excellent clinical 
response.
In conclusion, our two cases illustrate how 
important it is to suspect fungal aetiology of CNS 
infections. Furthermore, given the ever increasing list 
of documented fungal pathogens even in apparently 
immunocompetent individuals, both clinicians and 
microbiologists should become familiar with various 
fungi, their epidemiological and pathogenic features, 
and the optimal approaches to diagnosis and 
therapy.
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Sažetak
OPORTUNISTIČKE MIKOZE SREDIŠNJEGA ŽIVČANOG SUSTAVA – PRIKAZ DVAJU 
BOLESNIKA
U ovom radu prikazana su dva bolesnika oboljela od oportunističkih mikoza (OM) središnjega živčanog 
sustava uzrokovanih vrstama Cryptococcus neoformans i  Aspergillus nidulans. Bolesnici su bili 
hospitalizirani u lokalnim bolnicama od 2009. do 2011. godine zbog nespeciﬁ čnih simptoma (febrilitet, 
glavobolja i/ili gubitak tjelesne težine). Trajanje simptoma variralo je od 4 dana do više od 2 mjeseca. 
Bolesnici su bili liječeni antibioticima i simptomatski. Ni u jednog bolesnika nije postojala sumnja na OM. 
Kod oba bolesnika razvile su se teške kliničke slike infekcije sa simptomima zahvaćanja središnjega 
živčanog sustava i stoga su bili primljeni u Jedinicu intenzivnog liječenja Klinike za infektivne bolesti 
“Dr. F. Mihaljević” u Zagrebu. Nijedan bolesnik nije pripadao skupini bolesnika s najvećim rizikom od 
razvoja oportunističkih mikoza. Nisu bili inﬁ cirani HIV-om, niti su bili liječeni transplantacijom koštane 
srži ili solidnog organa, kao ni jakim imunosupresivnim lijekovima. Gljivični izolati izdvojeni su iz uzoraka 
likvora u jednog bolesnika, a u drugog bolesnika iz uzorka aspirata moždanog apscesa. Izolacija i mikološka 
identiﬁ kacija svih gljivičnih izolata i in vitro ispitivanje osjetljivosti gljivičnih izolata na antifungalne 
lijekove bili su provedeni u Referentnom centru za mikološku dijagnostiku sustavnih i diseminiranih 
infekcija (RCMDSDI) u Zagrebu. Amfotericin B i ﬂ ukonazol davani su za liječenje kriptokoknog 
meningitisa, a vorikonazol za liječenje aspergiloma mozga.
KLJUČNE RIJEČI: Aspergillus nidulans, Cryptococcus neoformans, SŽS
CORRESPONDING AUTHOR:
Emilija Mlinarić-Missoni
 Reference Centre for Mycological Diagnostics of Systemic 
and Disseminated Infections Croatian National Institute of 
Public Health
Rockefellerova 2, 10000 Zagreb, Croatia
E-mail: emilija.mlinaric-missoni@hzjz.hr
Mlinarić Missoni E, Baršić B. RARE CNS MYCOSES
Arh Hig Rada Toksikol 2012;63:505-511
